PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.
Wednesday morning, the West Virginia Mountaineers gained a commitment (and signature) from Cerritos College defensive line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback